Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2016', provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects - The report assesses Onychomycosis (Tinea Unguium) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Onychomycosis (Tinea Unguium) Overview 8 Therapeutics Development 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9 Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 10 Onychomycosis (Tinea Unguium) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Onychomycosis (Tinea Unguium) - Products under Development by Companies 15 Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 16 Eisai Co., Ltd. 16 Helix BioMedix, Inc. 17 Hexima Limited 18 Meiji Seika Pharma Co., Ltd. 19 Moberg Pharma AB 20 NAL Pharmaceuticals Ltd. 21 Nihon Nohyaku Co., Ltd. 22 Novabiotics Limited 23 Nuvo Research Inc. 24 Polichem S.A. 25 Viamet Pharmaceuticals, Inc. 26 Onychomycosis (Tinea Unguium) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 ELS-160 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 fosravuconazole - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 HB-1275 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 HXP-124 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 luliconazole - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ME-1111 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 NAL-3216 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 NP-213 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 terbinafine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 terbinafine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 terbinafine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 VT-1161 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 54 Onychomycosis (Tinea Unguium) - Dormant Projects 60 Onychomycosis (Tinea Unguium) - Discontinued Products 63 Onychomycosis (Tinea Unguium) - Product Development Milestones 64 Featured News & Press Releases 64 Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015 64 Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit 65 Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation 65 Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus) 65 Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology 66 Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis 66 Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis 67 Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 68 Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 68 Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H1 2016 16 Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H1 2016 17 Onychomycosis (Tinea Unguium) - Pipeline by Hexima Limited, H1 2016 18 Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 19 Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2016 20 Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 21 Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H1 2016 22 Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Limited, H1 2016 23 Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H1 2016 24 Onychomycosis (Tinea Unguium) - Pipeline by Polichem S.A., H1 2016 25 Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 26 Assessment by Monotherapy Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H1 2016 54 Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2016 60 Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..1), H1 2016 61 Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H1 2016 62 Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2016 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.